 | • レポートコード：MRC2303I0071 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界のクローン病診断＆治療市場規模が、予測期間中に年平均3.1%で成長すると予測しています。本レポートは、クローン病診断＆治療の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、診断別（血液検査、糞便検査、大腸内視鏡検査、軟性S状結腸鏡検査、その他）分析、治療別（投薬、手術）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Abbvie Inc.、Celgene Corporation、Genetech、Johnson & Johnson、Pfizer Inc.、Prometheus Laboratories Inc. (Nestle)、Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)、Takeda's Pharmaceutical Ltdなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のクローン病診断＆治療市場規模：診断別 - 血液検査の市場規模 - 糞便検査の市場規模 - 大腸内視鏡検査の市場規模 - 軟性S状結腸鏡検査の市場規模 - その他診断の市場規模 ・世界のクローン病診断＆治療市場規模：治療別 - 投薬の市場規模 - 手術の市場規模 ・世界のクローン病診断＆治療市場規模：地域別 - 北米のクローン病診断＆治療市場規模 アメリカのクローン病診断＆治療市場規模 カナダのクローン病診断＆治療市場規模 メキシコのクローン病診断＆治療市場規模 … - ヨーロッパのクローン病診断＆治療市場規模 ドイツのクローン病診断＆治療市場規模 イギリスのクローン病診断＆治療市場規模 フランスのクローン病診断＆治療市場規模 … - アジア太平洋のクローン病診断＆治療市場規模 中国のクローン病診断＆治療市場規模 日本のクローン病診断＆治療市場規模 インドのクローン病診断＆治療市場規模 … - 中東/南米のクローン病診断＆治療市場規模 南アフリカのクローン病診断＆治療市場規模 ブラジルのクローン病診断＆治療市場規模 アルゼンチンのクローン病診断＆治療市場規模 … - その他地域のクローン病診断＆治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The Crohn’s disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period.
With the rise in COVID-19, the prevalence of other related complications also increased. According to a report by the SECURE-IBD database in January 2022, adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with IBD. The novel severe acute respiratory syndrome-related coronavirus activated innate and adaptive immune responses upon entering the gastrointestinal tract. The study shows IBD patients’ inflammatory reactions may cause intestinal damage. Also, a research article published in the Journal of Crohn and Colitis in March 2020 showed that IBD patients undertaking immune suppressors are associated with a greater risk of infections, even though there is no evidence to suggest that COVID-19 affects IBD patients more commonly than the general population. According to a review article in the World Journal of Gastroenterology in October 2020, it was comprehended that many COVID-19 patients were found to develop gastrointestinal complaints. Thus, there is an increasing demand for the Crohn’s disease diagnostics and therapeutics market to manage further complications that could develop due to COVID-19.
The increasing occurrence of Crohn’s disease is the primary driver predicted to boost the growth of the market. According to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD is around 7 million worldwide. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney, and liver diseases are higher in IBD patients than in non-IBD patients. In the older population (66 years and above), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30-day readmissions, and more extended hospital stays. Studies on the treatment of IBD for the prevention of such instances are a great boost to the development of the market during the forecast period.
The increasing awareness of Crohn’s disease, coupled with rising initiatives by regulatory bodies to develop novel treatment options, is expected to provide the market studied with high growth potential.
Crohns Disease Diagnostic & Therapeutic Market Trends
The Anti-inflammatory Agents Segment is Expected to Witness Significant Growth During the Forecast Period
Anti-inflammatory agents have continued to lead as the largest sub-segment under the market’s therapeutics segment due to their higher efficacy than immunosuppressants and analgesics. A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for Crohn’s disease.
Additionally, the increasing investments, clinical trials, and key player activities are expected to contribute to the growth of the segment studied. For instance, in September 2022, rise therapeutics LLC received funding from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institute of Health to support proof-of-concept clinical testing of the therapeutic candidate, R-3750. It is an anti-inflammatory drug for the treatment of inflammatory bowel disease.
Similarly, in July 2021, Cerecord had positive initial phase 1 b results for CERC-002 in moderate to severe Crohn’s disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments. Thus the abovementioned factors are expected to drive the growth of the segment studied during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America holds the largest market share in the Crohn’s disease diagnostics and therapeutics market due to the increasing prevalence of the disease in the region. The increasing adoption of innovative medicines is expected to drive the demand for the Crohn’s disease diagnostics therapeutics market in the North American region. An increase in research and development in clinical-stage companies in novel treatments for the disease is predicted to boost the growth of the Crohn’s disease diagnostics therapeutics market in the region. In a study published in the Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in the United States.
In this region, urbanization is a potential factor contributing to the increasing prevalence of Crohn’s disease. The incidence of Crohn’s disease has been attributed to the “westernization” of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals. Also, the growth strategies of market players, such as partnerships, are expected to contribute to the growth of the market in this region. For instance, in January 2022, LifeArc partnered with the US-based Crohn’s and Colitis Foundation to develop a prognostic for Crohn’s disease in children. Thus the abovementioned factors are expected to drive the growth of the market in this region during the forecast period.
Crohns Disease Diagnostic & Therapeutic Market Competitor Analysis
The Crohn’s disease diagnostics and therapeutics market has growth opportunities in developing and developed nations. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some major market players include Pfizer Inc., Janssen Biotech Inc., GeneTech, Celgene Corporation, AbbVie Inc., and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
4.2.2 Demand for Prompt Diagnosis
4.2.3 Affected Population Increasing with Time
4.3 Market Restraints
4.3.1 No Specific Treatment or Drug Available in the Market
4.3.2 Lack of Awareness Among People and Symptom Similarity with Other Gastrointestinal Diseases
4.3.3 Lack of Cost-effective Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Diagnostics
5.1.1 Blood Test
5.1.2 Fecal Test
5.1.3 Colonoscopy
5.1.4 Flexible Sigmoidoscopy
5.1.5 Computerised Tomography
5.1.6 Magnetic Resonance Imaging
5.1.7 Other Diagnostic Tests
5.2 By Treatment
5.2.1 Medication
5.2.1.1 Anti-inflammatory Agents
5.2.1.2 Immunosuppressants
5.2.1.3 Analgesics and Antipyretics
5.2.1.4 Other Medications
5.2.2 Surgery
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Celgene Corporation
6.1.3 Genetech
6.1.4 Johnson & Johnson
6.1.5 Pfizer Inc.
6.1.6 Prometheus Laboratories Inc. (Nestle)
6.1.7 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
6.1.8 Takeda’s Pharmaceutical Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS